#### Characterization of Insulin-degrading Enzyme: Using Molecular Visualization Systems to Understand Substrate Recognition in Type 2 Diabetes and Alzheimer's

Aditi Kona

# Introduction

- **Amyloid beta** (Aβ) is a biomarker for Alzheimer's Disease (AD)
  - >  $A\beta$  plaques lead to AD
- Insulin is the principle regulator of Type 2 Diabetes (T2D)
  - Lack of insulin leads to T2D
- Both Abeta and insulin are found in endosomes
  - Internalized by receptor-mediated endocytosis
- What connect these disorders?

# Insulin-degrading Enzyme (IDE)

 $A\beta$  and insulin are substrates of IDE

(IDE activators) (IDE inhibitors)  $\downarrow$   $\downarrow$   $\downarrow$ Increases IDE = Inhibiting IDE = A $\beta$  degradation retention of insulin

How does IDE, a cytosolic enzyme, encounter A $\beta$  and insulin in the endosome?



# BACKGROUND

- Phosphatidylinositol phosphates (PtdInsPs) bind at the **polyanion binding site** to localize IDE to endosomes
- PtdInsPs serve as identifiers of different membranes
- Decreased localization of IDE = slowed T2D progression
- Increased localization of IDE = slowed AD progression

#### PtdInsPs distinguish different cell membranes.





Model for interaction between IDE and membrane bound PI(3)P.

### PROBLEM

- Polyanion binding site and active site overlap
  - Mutations in polyanion binding site could disrupt substrate degradation
- <1% of IDE is endosomal
  - High chance of off-target effects in cytosolic IDE





#### **RESEARCH QUESTION**

How can IDE be mutated such that it has a reduced ability to localize to endosomes but still retains full enzymatic activity?

#### HYPOTHESIS

Despite overlap between the polyanion binding site and the active site, residues/amino acids that mediate lipid headgroup binding can be mutated such that IDE's ability to bind to substrates is not disrupted.

## **PURPOSE AND OBJECTIVES**

**Purpose:** Create a Non-localizing Mutant of IDE

#### **Objectives:**

- **1.** Identify residues vital for substrate degradation
- 2. Identify residues of interest to mutate in the polyanion binding site
- 3. Apply research to create a mutant of IDE with increased localization



### **METHODS**

- Used molecular visualization systems and online servers to identify which residues are important for substrate binding
- Advantages of online macromolecular structure analysis
  - More efficient
  - Less expensive
  - Provides promising direction for wet-lab research



### **How Were Interactions Documented?**

The side chain is different for every residue and thus gives the residue its properties.

- Side chains differentiate residues
- 7 types of interactions between residues of substrate and IDE
  - Main chain hydrogen bonds (H-bonds)
  - Main chain van der Waals forces (VDWs)
  - Main chain water-mediated contacts
  - Side chain hydrogen bonds
  - Side chains van der Waals forces
  - Side chain water-mediated contacts
  - Side chain salt bridges
- Interactions were cataloged in Excel Sheet



	IDE		Main_VDW	Main_hbond	Side_hbond	Side_VDW
135	A (Ala)					
136	G (Gly)					
137	S (Ser)					
138	S (Ser)					
139	N (Asn)	,	17 Leu	17 Leu	18 Val [two H- bonds]	17 Leu 18 Val
140	A (Ala)		16 Tyr 17 Leu	17 Leu		17 Leu
141	F (Phe)		15 Leu 16 Tyr			15 Leu 16 Tyr
142	T (Thr)		14 Ala 15 Leu	15 Leu [two H- bonds]		15 Leu
143	S (Ser)		14 Ala			14 Ala

Snippet of cataloged main chain VDWs, main chain H-bonds, side chain VDWs, and side chain H-bonds between IDE and insulin b chain.







PyMol Viewer and Graphical User Interface. Pictured is upper control panel, display area, object menu panel, and mouse controls. Sequence alignment shows residues of IDE, insulin B, and water molecules. Insulin B chain residues were selected and copied into a new object titled "insulin\_b." Object was colored magenta.





PyMol view with cartoon representation hidden. Main chains were shown as sticks and side chains were shown as lines to differentiate by thickness. Hydrogen bonds, represented by dashed yellow lines, were found in the object. PyMol view highlighting residue 1 of insulin and the three main chain H-bonds and 1 side chain H-bonds it makes with IDE residues.







PyMol view showing water-mediated contacts.

PyMol view showing residues within 4 Å of the insulin substrate. Sequence alignment highlights selected residues of interest for salt bridges.



#### Non-bonded contacts

<----> A T O M 1 ----> <----> A T O M 2 ----> Atom Atom Res Atom Atom Res Res Res no. name name no. Chain no. name name no. Chain Distance 1. 516 NE2 GLN 111 A <--> 61949 0 SER 12 а 3.51 2. 523 ND1 HIS 112 А <--> 61966 CD1 TYR 14 3.21 3. 523 ND1 HIS 112 А <--> 61968 CE1 TYR 14 3.18 а 4. 525 CE1 HIS 112 А <--> 61966 CD1 TYR 14 3.33 а 3.62 5. 525 CE1 HIS 112 А <--> 61968 CE1 TYR 14 6. 733 <--> 61980 3.64 C SER 138 А NE2 GLN 15 а 7. 734 0 SER 138 А <--> 61978 CD GLN 15 а 3.67 8. 734 0 SER 138 А <--> 61980 NE2 GLN 15 2.46 9. 741 CB ASN 139 А <--> 61980 NE2 GL.N 15 3.69 742 3.47 10. CG ASN 139 A <--> 61956 CB LEU 13 11. 742 CG ASN 139 <--> 61960 TYR 14 3.45 12. 742 CG ASN 139 А <--> 61972 GLN 15 3.84 13. 742 CG ASN 139 Δ <--> 61975 GL.N 15 3.57 0 14. 742 ASN 139 15 3.30 CG <--> 61980 NE2 GLN 15. 743 OD1 ASN 139 <--> 61953 13 3.40 А CA LEU 16. 743 OD1 ASN 139 <--> 61954 3.13 А C LEU 13 а 17. 743 OD1 ASN 139 <--> 61956 LEU 13 3.38 А CB 2.37 18. 743 OD1 ASN 139 A <--> 61960 N TYR 14 19. 743 OD1 ASN 139 <--> 61961 TYR 3.22 А CA 14 а 20. 743 OD1 ASN 139 А <--> 61962 C TYR 14 3.78 21. 743 OD1 ASN 139 <--> 61964 CB TYR 3.25 А 22. 743 OD1 ASN 139 Α <--> 61972 N GL.N 15 3.34 23. 3.88 743 OD1 ASN 139 A <--> 61980 NE2 GL-N 15 3.37 24. 744 ND2 ASN 139 А <--> 61956 CB LEU 13 25. 744 ND2 ASN 139 <--> 61957 CG LEU 13 3.40 А 26. 3.30 744 ND2 ASN 139 А <--> 61958 CD1 LEU 13 27. 744 ND2 ASN 139 А <--> 61972 GLN 15 3.62 28. 744 ND2 ASN 3.59 139 А <--> 61974 GLN 15 а 29. 744 ND2 ASN 139 А <--> 61975 0 GLN 15 2.47 30. 744 ND2 ASN 139 А <--> 61978 CD GLN 15 3.80 31. 744 ND2 ASN 139 А <--> 61980 NE2 GLN 15 3.04 а 32. 748 O ALA 3.15 140 А <--> 61949 0 SER 12 33. 748 ALA 140 <--> 61953 13 3.16 0 А CA LEU 34. 748 O ALA 140 Α <--> 61954 C LEU 13 3.49 35 748 ALA. 140 <--> 61960 TYP 2.97 36. 751 3.37 CA PHE 141 А <--> 61949 0 SER 12 а 37. 754 CB PHE 141 А <--> 61946 SER 12 3.79 а 38. 754 CB PHE 141 А <--> 61948 C SER 12 а 3.77 39. 754 CB PHE 141 А <--> 61949 0 SER 12 а 3.58 40. 769 SER <==> 61938 A CG2 ILF 41. 772 CB SER 143 A <--> 61938 CG2 ILE 10 3.40 a 42. 835 OH TYR 150 A <--> 61956 CB LEU 13 3.79 a





#### PyMol view of IDE residue 141, which was colored cyan.

Residue 141 is labeled with atom names.

PDBSum list of Non-bonded contacts.

3.64

# Arpeggio



Arpeggio overview. Each type of interaction is broken down.



#### Arpeggio PyMol output with breakdown of each interaction to the right.



Undefined-proximity set is depicted by red dashed lines between residues.

### Worldwide Protein Data Bank (wwPDB)

RCSB PDB Deposit - Search - Visualize - A	nalyze - Download - Learn - More - Do	cumentation -	МуРДВ 🗸
PROTEIN DATA BANK Research and Education	tures hs in on Advanced Search   Browse Annotation	Celebrating	RS OF Tein Data Bank
Structure Summary 3D View Annotations	Experiment Sequence Genome		
Biological Assembly 1 0	2G556 crystal structure of human insulin-d D0I: 10.2210/pdb2G56/pdb Classification: HYDROLASE Organism(s): Homo sapiens Expression System: Escherichia coli Mutation(s): Yes € Deposited: 2006-02-22 Released: 2006-10-24 Deposition Author(s): Shen, Y., Tang, WJ.	legrading enzyme in complex wi	ay Files ▼
	Experimental Data Snapshot Method: X-RAY DIFFRACTION Resolution: 2.20 Å B-Value Free: 0.225	wwPDB Validation ① Metric Pero Rfree	© 3D Report Full Report centile Ranks Value 0.214
3D View: Structure   Electron Density   Ligand Interaction	R-Value Work: 0.205 R-Value Observed: 0.205	Ramachandran outliers Sidechain outliers RSRZ outliers	0.1% 5.8%

#### wwPDB summary of structure 2g56.

2( cry X-	G56 stal structure of human insulin- RAY DIFFRACTION	degi	rading enzyr	ne in complex wit	h insulin I	3 chain	Display Files - O Download Files -
Cr	ystallization						
Cry	- stalization Experiments						
ID	Method	pН	Temperature	Details			
1	VAPOR DIFFUSION, HANGING DROP	7	298	PEGMME5000, dioxa	ne, tacismate	, hepes, pH 7.0, VAPOR DIFFUSION, HA	NGING DROP, temperature 298K
Cry	rstal Properties						
Ma	tthews coefficient					Solvent content	
3.8						67.67	
Cr Un	ystal Data <sup>it Cell</sup>				Symme	try	
Le	ngth (Å)	A	ngle (°)		Space (	Group	P 65
a =	262.25	α	= 90				
b =	262.25	β	= 90				
c =	90.61	γ	= 120				

#### Experimental data for structure 2g56, which was determined using x-ray diffraction.

Entity ID: 1						Entity ID: 2					
Molecule	Chains	Sequence Length	Organism	Details	Image	Molecule	Chains	Sequence Length	Organism	Details	Image
Insulin-degrading enzyme	Α, Β	990	<u>Homo sapiens</u>	Mutation(s): 1 Gene Names: IDE EC: <u>3.4.24.56</u>		Insulin	C, D	30	N/A	Mutation(s): 0	7

Breakdown of proteins in structure. In structure 2G56, there are two IDE chains and two insulin chains.

## **DATA/RESULTS**

#### Protein Data Bank structures I analyzed:



2G56	5WOB	6BFC	2G47_2WBY
Crystal structure of IDE in complex with insulin B chain	Crystal Structure Analysis of Fab1-Bound IDE in Complex with insulin A	Cryo-EM structure of IDE in complex with insulin B	Crystal structure of IDE in complex with amyloid-beta and insulin A and B chain
	in the second		









### RESULTS

4	structures	3 structures	2 structures	1 structure
IDE residues	111 Gln 139 Asn 140 Ala 141 Phe 199 Trp 824 Arg 831 Tyr	108 His 112 His 142 Thr 150 Tyr 198 Ala 202 Phe 339 Gly 359 Leu 361 Gly 363 Gln 436 Lys 683 Met 820 Phe	115 Phe 143 Ser 182 Glu 189 Glu 220 Thr 332 His 360 Val 362 Gly 374 Ile 431 Arg 609 Tyr 679 His 680 Gln 834 Phe	47 IIe 48 Lys 49 Arg 138 Ser 192 Lys 331 Gly 335 Gly 336 His 341 Glu 364 Lys 429 Arg 432 Gly 677 Gln 816 Ser 849 IIe

# **Residue 111 Glutamine**

 $\bullet \bullet \bullet \bullet \circ \bullet$ 



In structure 2G47\_2WBY, residue 111 of IDE (shown in cyan) forms a side chain H-bond with residue 20 of  $A\beta$  and residue 1 of insulin.

In structure 5WOB, residue 111 forms a side chain H-bond with residue 12 of insulin.

ſ		Atom	Atom	Res	Res			Atom	Atom	Res	Res		
		no.	name	name	no.	Chain		no.	name	name	no.	Chain	Distance
	1.	8203	ND1	HIS	108	в	<>	15671	CB	HIS	10	b	3.74
L	2.	8205	CE1	HIS	108	В	<>	15671	CB	HIS	10	b	3.62
	3.	8233	OE1	GLU	111	в	<>	15691	CG2	VAL	12	b	3.27
	4.	8268	CD2	PHE	115	В	<>	15690	CG1	VAL	12	b	3.75

In structure 6BFC, residue 111 makes a side chain VDW contact with residue 12 of the insulin B chain.

	Atom	Atom	Res	Res			Atom	Atom	Res	Res			
	no.	name	name	no.	Chain		no.	name	name	no.	Chain	Distance	
1.	478	CD2	HIS	108	A	<>	15760	CB	LEU	15	C	3.81	
2.	479	CE1	HIS	108	A	<>	15760	CB	LEU	15	С	3.71	
3.	480	NE2	HIS	108	A	<>	15760	CB	LEU	15	C	3.43	
4.	480	NE2	HIS	108	A	<>	15764	0	TYR	16	C	3.75	
5.	505	OE1	GLN	111	A	<>	15759	0	LEU	15	С	3.39	
6.	506	NE2	GLN	111	A	<>	15766	N	LEU	17	С	3.51	
7.	506	NE2	GLN	111	A	<>	15767	CA	LEU	17	С	3.42	
8.	506	NE2	GLN	111	A	<>	15770	CB	LEU	17	С	3.24	
9.	515	CE1	HIS	112	A	<>	15769	0	LEU	17	С	3.84	
10.	516	NE2	HIS	112	A	<>	15764	0	TYR	16	с	3.77	
11.	732	CG	ASN	139	A	<>	15771	N	VAL	18	С	3.89	

In structure 2G56, residue 111 forms a side chain VDW contact with residues 15 and 17 of insulin.

#### ......



## **Residue 139 Asparagine**



In structure 2G56, residue 139 of IDE (shown in green) forms two side chain H-bonds with residue 18.



In structure 2G47\_2WBY, residue 139 of IDE forms a main chain H-bond with residue 20 of  $A\beta$  and a water-mediated contact.



In structure 5WOB, residue 139 forms a side chain H-bond with residue 14 and residue 15 of insulin.

	34.00	34.00	Dee	Dee			74.000	D do como	Dee	Dee		
	ALOM	ACOM	nes	nes	a		ACOM	ALOM	res	nes	an - 1 -	
	no.	name	name	no.	Chain		no.	name	name	по.	Chain	Distance
1.	8203	NDI	HIS	108	в	<>	15671	СВ	HIS	10	D	3.74
2.	8205	CE1	HIS	108	в	<>	15671	CB	HIS	10	b	3.62
3.	8233	OE1	GLU	111	в	<>	15691	CG2	VAL	12	b	3.27
4.	8268	CD2	PHE	115	в	<>	15690	CG1	VAL	12	b	3.75
5.	8270	CE2	PHE	115	в	<>	15690	CG1	VAL	12	b	3.66
6.	8270	CE2	PHE	115	В	<>	15691	CG2	VAL	12	b	3.84
7.	8460	CG	ASN	139	в	<>	15684	CD2	LEU	11	b	3.86
8.	8460	CG	ASN	139	в	<>	15685	N	VAL	12	b	3.86
9.	8460	CG	ASN	139	в	<>	15692	N	GLU	13	b	3.73
10.	8460	CG	ASN	139	в	<>	15695	0	GLU	13	b	3.70
11.	8461	OD1	ASN	139	в	<>	15678	CA	LEU	11	b	3.83
12.	8461	OD1	ASN	139	в	<>	15679	с	LEU	11	b	3.79
13.	8461	OD1	ASN	139	в	<>	15681	CB	LEU	11	b	3.53
14.	8461	OD1	ASN	139	в	<>	15684	CD2	LEU	11	b	3.76
15.	8461	OD1	ASN	139	в	<>	15685	N	VAL	12	b	2.81
16.	8461	OD1	ASN	139	в	<>	15686	CA	VAL	12	b	3.53
17.	8461	OD1	ASN	139	в	<>	15689	CB	VAL	12	b	3.44
18.	8461	OD1	ASN	139	в	<>	15691	CG2	VAL.	12	b	3.86
19.	8461	OD1	ASN	139	в	<>	15692	N	GLU	13	b	3.39
20.	8462	ND2	ASN	139	в	<>	15681	CB	LEU	11	b	3.57
21	8462	ND2	ASN	139	в	<>	15682	CG	LEU	11	h	3.84
22	8462	ND2	ASN	139	B	<>	15683	CD1	LEU	11	ñ	3.80
22	9462	MD2	ACM	120	5		15694	CD2	TEU	11	ĥ	2 59
24	9462	ND2	AGN	139	5	2>	15692	N	CLU	13	ĥ	3.70
25	0462	ND2	B.CN	120		2	15604		CLU	12	2	3.70
25.	0402	ND2	ACM	120	D	2	15605	č	CLU	12	5	3.72
27	9466	0	ALA	140	P	2 2	15670	0	HTC	10		2 27

In structure 6BFC, residue 139 forms side chain VDW contacts with residues 11, 12, and 13 of insulin.

#### .......

# CONCLUSIONS

- Amino acids that mediate substrate degradation are not part of the polyanion binding site
- Minimal off-target effects
- Research tells us how to make mutations with minimal disruption to substrate interactions
- Hypothesis was accepted
  - Although polyanion binding site and active site partially overlap, most of the residues that likely mediate lipid headgroup interactions are not used to bind substrates

### **FUTURE DIRECTIONS**

- Protein docking
  - Ο Predict orientation of ligand when bound to enzyme
- Promising candidates to mutate in-lab •

Status

If you can selectively inhibit IDE, you can slow degradation of insulin or even improve length of time over which insulin acts



Job ID	91429
Job Name	gpi4p_2g47_repeat
Visibility	PUBLIC (you can share this job)
Protocol	Ligand Docking
CPU hours used	20.9
user	aditikona
Status	Finished
Daemon	GrayLab.Rosetta-2
Description	
angle_step	5.0
chain	x
gen_conformers	True
grid_width	15.0
highres_cycles	6
highres_repack_cycles	3
initial_perturb	3.0
move_step	0.1
n_ligand_conformers	200
nstruct	400
pocket_width	7.0
transform_cycles	500
use_input_position	False
x_start	85.3908081055
y_start	71.4642181396
z_start	3.0
Submitted time	2021-02-22 14:48
Start time	2021-02-22 14:49
End time	2021-02-22 15:13



Score data [D	ownload orig	inal score file	1							0
decoy	interface_delt	total_score	Transform_acc	angle_constra	atom_pair_cor	chainbreak	coordinate_co	dihedral_const	dslf_ca_dih	dslf_cs_an
protein LG 03	-5.888	-1013.911	0.504	0	0	0	2.677	0	0	0
protein LG 03	-5.228	-1016.262	0.5	0	0	0	3.445	0	0	0
protein_LG_02	-5.225	-1002.216	0.598	0	0	0	3.178	0	0	0
protein LG 01	-5.103	-986.614	0.546	0	0	0	1.523	0	0	0
protein LG 02	-4.923	-1008.829	0.536	0	0	0	3.197	0.004	0	0
protein_LG_01	-4.535	-1024.81	0.56	0	0	0	3.885	0	0	0
protein_LG_03	-4.434	-1019.21	0.566	0	0	0	3.113	0	0	0
protein LG 03	-4.414	-983.876	0.538	0	0	0	3.198	0	0	0

Ligand Docking Job gpi4p 2g47 repeat 「№91429」 Details

### REFERENCES

Abdul-Hay, S. O., Kang, D., McBride, M., Li, L., Zhao, J., & Leissring, M. A. (2011). Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PloS one, 6(6), e20818. https://doi.org/10.1371/journal.pone.0020818

Hulse, R. E., Ralat, L. A., & Wei-Jen, T. (2009). Structure, function, and regulation of insulin-degrading enzyme. Vitamins and hormones, 80, 635–648. <u>https://doi.org/10.1016/S0083-6729(08)00622-5</u>

Noinaj, N., Song, E. S., Bhasin, S., Alper, B. J., Schmidt, W. K., Hersh, L. B., & Rodgers, D. W. (2012). Anion activation site of insulin-degrading enzyme. The Journal of biological chemistry, 287(1), 48–57. https://doi.org/10.1074/jbc.M111.264614

Song, E. S., Ozbil, M., Zhang, T., Sheetz, M., Lee, D., Tran, D., Li, S., Prabhakar, R., Hersh, L. B., & Rodgers, D. W. (2015). An Extended Polyanion Activation Surface in Insulin Degrading Enzyme. PloS one, 10(7), e0133114. https://doi.org/10.1371/journal.pone.0133114

Song, E. S., Jang, H., Guo, H. F., Juliano, M. A., Juliano, L., Morris, A. J., Galperin, E., Rodgers, D. W., & Hersh, L. B. (2017). Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes. Proceedings of the National Academy of Sciences of the United States of America, 114(14), E2826–E2835. https://doi.org/10.1073/pnas.1613447114

#### ACKNOWLEDGMENTS

Thank you to Dr. David Rodgers for providing remote guidance through this project.